Expiration date: 05/2026

Composition 

one capsule contains: 

active substance-Trombovazim® 400 or 800 UNITS, excipients:

Potato starch 0, 261 g, microcrystalline Cellulose 0, 120 g, Sodium chloride 0, 009 g the gelatin capsule includes: Dyes: azorubin E 122, patent blue V E 131, titanium dioxide E 171, gelatin.

Pharmacological action

The drug has thrombolytic, anti-inflammatory and cardioprotective effects.

Pharmacodynamics

The mechanism of thrombolytic action is associated with the direct destruction of the fibrin filaments that form the main frame of the thrombus. The mechanism of anti-inflammatory action is associated with the effect on the oxidative function of blood neutrophils and tissue macrophages. The mechanism of cardioprotective action is associated with improved blood supply to the myocardium. Thrombovazim® is a low-toxicity drug. Trombovazim® does not reduces the level of platelets and does not affect the clotting time and duration of bleeding.

Pharmacokinetics

The bioavailability of the drug when taken orally is 16 %-18 %. The maximum effect occurs after 6 hours. The total clearance is 1, 2 ml / min, the elimination rate constant for a single dose is 0, 057 min-1. The half-life of the drug when measuring specific activity in the blood is 12 minutes. It does not bind to plasma proteins and shaped elements. It does not accumulate in the body if the recommended doses and frequency of administration are observed. The main route of excretion of the drug through the kidneys (80 %). Partially metabolized and excreted by the liver (about 20 %). Side effects may be allergic reactions, in rare cases, dyspeptic phenomena (nausea, vomiting, a feeling of heaviness in the stomach). There may be a temporary feeling of distension in the lower extremities.